NEOS Investment Management LLC Grows Holdings in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

NEOS Investment Management LLC boosted its position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 51.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 30,811 shares of the company’s stock after purchasing an additional 10,433 shares during the period. NEOS Investment Management LLC’s holdings in SpringWorks Therapeutics were worth $1,113,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SWTX. AlphaQuest LLC grew its holdings in shares of SpringWorks Therapeutics by 70.2% in the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after acquiring an additional 414 shares in the last quarter. Venturi Wealth Management LLC bought a new position in SpringWorks Therapeutics in the 4th quarter valued at $45,000. KBC Group NV grew its stake in SpringWorks Therapeutics by 59.1% in the 4th quarter. KBC Group NV now owns 2,634 shares of the company’s stock valued at $95,000 after purchasing an additional 978 shares during the period. Quantbot Technologies LP purchased a new stake in shares of SpringWorks Therapeutics during the 3rd quarter valued at $147,000. Finally, US Bancorp DE boosted its holdings in shares of SpringWorks Therapeutics by 56.0% in the 4th quarter. US Bancorp DE now owns 4,336 shares of the company’s stock worth $157,000 after buying an additional 1,556 shares during the last quarter.

Insider Buying and Selling at SpringWorks Therapeutics

In other SpringWorks Therapeutics news, insider Daniel Pichl sold 29,750 shares of the firm’s stock in a transaction on Monday, February 10th. The shares were sold at an average price of $54.36, for a total value of $1,617,210.00. Following the completion of the transaction, the insider now directly owns 50,762 shares of the company’s stock, valued at $2,759,422.32. This trade represents a 36.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavesh Ashar sold 1,016 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $61.19, for a total transaction of $62,169.04. Following the completion of the transaction, the insider now directly owns 62,053 shares in the company, valued at approximately $3,797,023.07. The trade was a 1.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 440,766 shares of company stock valued at $24,402,956 in the last quarter. 7.61% of the stock is currently owned by corporate insiders.

SpringWorks Therapeutics Trading Down 0.2 %

SWTX opened at $47.41 on Friday. SpringWorks Therapeutics, Inc. has a 12 month low of $28.21 and a 12 month high of $62.00. The company has a market cap of $3.55 billion, a PE ratio of -13.62 and a beta of 0.76. The company has a 50 day moving average of $47.98 and a 200 day moving average of $39.75.

SpringWorks Therapeutics (NASDAQ:SWTX) last posted its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. The company had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. Research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on SWTX shares. Wedbush restated an “outperform” rating and set a $81.00 price objective on shares of SpringWorks Therapeutics in a report on Thursday, February 20th. Evercore ISI lifted their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, February 12th. Guggenheim reduced their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, HC Wainwright restated a “buy” rating and issued a $74.00 target price on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $73.20.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.